Each year in the U.S. alone, almost one million people with coronary artery disease are treated with a PCI; worldwide the number is about 2.1 million, which places the current market for drug-eluting stents (DES) in the seven major world healthcare markets at $4.9 billion, according to a new report from Kalorama Information.
Kalorama noted that stents are delivered into the artery during about 70 percent of PCI procedures.
The market effects of DES began in 2003, and today, they represent 69.2 percent of the total coronary stent market, which is expected to grow at a rate of about 4.6 percent now that the shock that surrounded the alleged DES problems has dissipated, according to the report.
“Though DES cost three to four times as much as bare metal stents, when one examines their cost-effectiveness, the case is clear,” noted Kenneth Krul, Kalorama analyst. “They remain an exciting innovation that will be a major part of cardiovascular intervention technologies over the next ten years, and it should become increasingly evident that DES use does in fact result in reduced long-term healthcare costs and improved economic outcomes.”
The market analysis in the Kalorama report covers seven major world healthcare markets: U.S., France, Germany, Italy, Japan, Spain and the United Kingdom.